Dana L. Holmes Jr.
Through the years 2004 and 2007, there was a clinical trial conducted by the National Institutes of Health to test an experimental HIV vaccine. This “test-of concept” study was the STEP vaccine trail-Phase IIB (National Institutes of Health, 2007). The STEP trial was created to clinically study the effectiveness of a new HIV vaccine that was supposed to engage the immune system to create T-cells which can damage cells infected with the HIV virus. This trial was designed to compare the scientific results of those who received the experimental vaccine in either one dose or two, against those who received a placebo.
Prior to beginning this study, the risks and benefits of the study would need to be explained to the participants of this experimental human trial. Due to the nature of the infectious diseased involved with this trial, and according to an article titled Understanding Differences in Enrollment Outcomes Among High-Risk Populations Recruited to a Phase IIb HIV Vaccine Trial, “Our study recruitment approach featured a key message on the urgent need for an HIV vaccine, and the campaign advertising included diverse and recognizable community members” (Frew, & del Rio, et al., 2009, Methods Study Sample/para. 1). Study participants would have been selected due to their eligibility for the specific study which was requiring volunteers to be in the age range of 18-45, currently be HIV negative, and have a lifestyle that put them at a higher chance of potential HIV infection.